V2 receptor antagonism with tolvaptan in heart failure

Expert Opinion on Investigational Drugs

Volumn 16, Issue 10, 2007, Pages 1639-1647

  Costello Boerrigter, Lisa C ^a   Boerrigter, Guido ^a   Burnett, John C ^a  

^a MAYO CLINIC   (United States)

Author keywords

Aquaretic; Arginine vasopressin; Heart failure; Pharmacology; Tolvaptan; Vasopressin 2 receptor antagonist

Indexed keywords

1 [1 [4 (3 ACETAMIDOPROPOXY)BENZOYL] 4 PIPERIDYL] 1,2,3,4 TETRAHYDRO 2 QUINOLINONE; 1 [5 CHLORO 1 (2,4 DIMETHOXYLPHENYLSULFONYL) 2,3 DIHYDRO 3 (2 METHOXYPHENYL) 2 OXO 1H INDOL 3 YL] 4 HYDROXY N,N DIMETHYL 2 PYRROLIDINECARBOXAMIDE; AMIODARONE; ARGIPRESSIN; CONIVAPTAN; CREATININE; DIURETIC AGENT; FUROSEMIDE; KETOCONAZOLE; LIXIVAPTAN; LOOP DIURETIC AGENT; MOZAVAPTAN; N TERT BUTYL 4 [5' ETHOXY 4 (2 MORPHOLINOETHOXY) 2' OXOSPIRO[CYCLOHEXANE 1,3' INDOLE] 1' SULFONYL] 3 METHOXYBENZAMIDE; NITROGEN; PLACEBO; POTASSIUM; RELCOVAPTAN; RWJ 351647; SATAVAPTAN; SODIUM; THIAZIDE DIURETIC AGENT; TOLVAPTAN; UNCLASSIFIED DRUG; UREA; VASOPRESSIN ANTAGONIST; VASOPRESSIN V2 RECEPTOR; YM 218; BENZAZEPINE DERIVATIVE; VASOPRESSIN RECEPTOR;

AREA UNDER THE CURVE; BLOOD PRESSURE; BODY WEIGHT; CLINICAL TRIAL; COMPETITIVE INHIBITION; COUGHING; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLUID INTAKE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART RATE; HEART VENTRICLE REMODELING; HUMAN; HYPERNATREMIA; HYPOKALEMIA; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; KIDNEY FUNCTION; NONHUMAN; POTASSIUM BLOOD LEVEL; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SODIUM EXCRETION; STRUCTURE ANALYSIS; THIRST; UREA NITROGEN BLOOD LEVEL; VASOPRESSIN BLOOD LEVEL; XEROSTOMIA; ANIMAL; CONGESTIVE HEART FAILURE; DRUG ANTAGONISM; METABOLISM;

ANIMALS; ARGININE VASOPRESSIN; BENZAZEPINES; CLINICAL TRIALS; DIURETICS; HEART FAILURE, CONGESTIVE; HUMANS; RECEPTORS, VASOPRESSIN;

EID: 35248815644     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.10.1639     Document Type: Review

References (31)

1. ROSAMOND W, FLEGAL K, FRIDAY G et al.: Heart disease and stroke statistics - 2007 update: a report from the American heart association statistics committee and stroke statistics subcommittee. Circulation (2007) 115(5):E69-E171.
2. HILLEGE HL, GIRBES AR, DE KAM PJ et al.: Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circualtion (2000) 102(2):203-210.
3. HILLEGE HL, NITSCH D, PFEFFER MA et al.: Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation (2006) 113(5):671-678.
4. SMILDE TD, VAN VELDHUISEN DJ, NAVIS G et al.: Drawbacks and prognosti value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. Circulation (2006) 114(15):1572-1580.
5. COOPER HA, DRIES DL, DAVIS CE et al.: Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation (1999) 100(12):1311-1315.
6. DRIES DL, EXNER DV, DOMANSKI MJ et al.: The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J. Am. Coll. Cardiol. (2000) 35(3):681-689.
7. GHEORGHIADE M, NIAZI I, OUYANG J et al.: Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation (2003) 107(21):2690-2696.
8. GHEORGHIADE M, GATTIS WA, O'CONNOR CM et al.: Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA (2004) 291(16):1963-1971.
9. GHEORGHIADE M, KONSTAM MA, BURNETT JC Jr et al.: Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials. JAMA (2007) 297(12):1332-1343.
10. KONSTAM MA, GHEORGHIADE M, BURNETT JC Jr et al.: Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA (2007) 297(12):1319-1331.
11. GOTTLIEB SS, BRATER DC, THOMAS I et al.: BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation (2002) 105(11):1348-1353.
12. PUBLICATION COMMITTEE FOR THE VMAC INVESTIGATORS (VASODILATATION IN THE MANAGEMENT OF ACUTE CHF): Intravenous nesiritide versus nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA (2002) 287(12):1531-1540.
13. COSTANZO MR, GUGLIN ME, SALTZBERG MT et al.: Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J. Am. Coll. Cardiol. (2007) 49(6):675-683.
14. BIRNBAUMER M: Vasopressin receptors. Trends Endocrinol. Metab. (2000) 11(10):406-410.
15. NIELSEN S, FROKIAER J, MARPLES D et al.: Aquaporins in the kidney: from molecules to medicine. Physiol. Rev. (2002) 82(1):205-244.
16. WANG BC, GINTER GF, GOETZ KL: Augmented pressor response to vasopressin in awake dogs after cardiac denervation. Am. J. Physiol. (1987) 252(1 Part 2):R145-R152.
17. TERANISHI Y, SUGINO H, OZONO R et al.: Contribution of endogenous vasopressin to regional hemodynamics in borderline-hypertensive Hiroshima rats. Hypertens. Res. (2002) 25(2):241-248.
18. YAMAMURA Y, NAKAMURA S, ITOH S et al.: OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J. Pharmacol. Exp. Ther. (1998) 287(3):860-867.
19. HIRANO T, YAMAMURA Y, NAKAMURA S et al.: Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J. Pharmacol. Exp. Ther. (2000) 292(1):288-294.
20. COSTELLO-BOERRIGTER LC, SMITH WB, BOERRIGTER G et al.: Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am. J. Physiol. Renal Physiol. (2006) 290(2):F273-F278.
21. HAUPTMAN PJ, ZIMMER C, UDELSON J et al.: Comparison of two doses and dosing regimens of tolvaptan in congestive heart failure. J. Cardiovasc. Pharmacol. (2005) 46(5):609-614.
22. RANGASETTY UC, GHEORGHIADE M, URETSKY BF et al.: Tolvaptan: a selective vasopressin type 2 receptor antagonist in congestive heart failure. Expert Opin. Investig. Drugs (2006) 15(5):533-540.
23. SHOAF SE, ELIZARI MV, WANG Z et al.: Tolvaptan administration does not affect steadv state amiodarone concentrations in patients with cardiac arrhythmias. J. Cardiovasc. Pharmacol. Ther. (2005) 10(3):165-171.
24. SHOAF SE, WANG Z, MALLIKAARJUN S et al.: Lack of clinically significant interaction between steady date tolvaptan and digoxin in healthy volunteers. Annual Meeting of American Society for Clinical Pharmacology and Therapeutics, Washington, DC, USA, (2-5 April 2003):PI-129.
25. WANG Z, SHOAF SE, KUMARA S et al.: Lack of effect of tolvaptan on pharmacokinetics (PK) and pharmacodynamics (PD) of warfarin. Annual Meeting of American Society for Clinical Pharmacology and Therapeeutics, Washington, DC, USA, 2-5 April (2003):PII-60.
26. NICCO, C, WITTNER M, DISTEFANO A et al.: Chronic exposure to vasopressin upregulates ENaC and sodium transport in the rat renal collecting duct and lung. Hypertension (2001) 38(5):1143-1149.
27. BANKIR L, FERNANDES S, BARDOUX P et al.: Vasopressin-V2 receptor stimulation reduces sodium excretion in healthy humans. J. Am. Soc. Nephrol. (2005) 16(7):1920-1928.
28. UDELSON JE, MCGREW FA, FLORES E et al.: Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J. Am. Coll Cardiol. (2007) 49(22):2151-2159.
29. SCHRIER RW, GROSS P GHEORGHIADE M et al.: Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N. Engl. J. Med. (2006) 355(20):2099-2112.
30. UDELSON JE, SMITH WB, HENDRIX GH et al.: Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation (2001) 104(20):2417-2423.
31. GHALI JK, KOREN MJ, TAYLOR JR et al.: Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J. Clin. Endocrinol. Metab. (2006) 91(6):2145-2152.